Brain F-FDG PET analysis via interval-valued reconstruction: proof of concept for Alzheimer's disease diagnosis.

Ann Nucl Med

Département de médecine nucléaire, Montpellier University Hospital, CHU Lapeyronie, 191 av. du Doyen Giraud, 34295, Montpellier cedex 5, France.

Published: August 2020

AI Article Synopsis

  • The study introduces a new method for analyzing brain F-FDG PET scans to diagnose Alzheimer's disease (AD) by using an interval-valued reconstruction approach called NIBEM.
  • Brain scan data from 26 subjects were compared using this new method and a validated automated software (Scenium), focusing on specific brain regions affected by AD.
  • Both methods showed similar high accuracy for distinguishing between healthy individuals and AD patients, indicating that the interval-valued method could be a viable alternative to traditional software for diagnosing Alzheimer's.

Article Abstract

Objective: We propose an innovative approach for F-FDG PET analysis based on an interval-valued reconstruction of F-FDG brain distribution. Its diagnostic performance for Alzheimer's disease (AD) diagnosis with comparison to a validated post-processing software was assessed.

Methods: Brain F-FDG PET data from 26 subjects were acquired in a clinical routine setting. Raw data were reconstructed using an interval-valued version of the ML-EM algorithm called NIBEM that stands for Non-Additive interval-based expectation maximization. Subject classification was obtained via interval-based statistical comparison (intersection ratio, IR) between cortical regions of interest (ROI) including parietal, temporal, and temporo-mesial cortices and a reference region, the sub-cortical grey nuclei, known not to be affected by AD. In parallel, PET images were post-processed using a validated automated software based on the computation of ROI normalized uptake ratios standard deviation (SUVr SD) with reference to a healthy control database (Siemens Scenium). Clinical diagnosis made during follow-up was considered as the gold-standard for patient classification (16 healthy controls and 10 AD patients).

Results: Both methods provided cortical ROI indices that were significantly different between controls and AD patients. The area under the ROC curve for control/AD classification was statistically identical (0.96 for NIBEM IR and 0.95 for Scenium SUVr SD). At the optimal threshold, the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were, respectively, 100%, 88%, 92%, 83%, and 100% for both Scenium SUVr SD and NIBEM IR methods.

Conclusion: This preliminary study shows that interval-valued reconstruction allows self-consistent analysis of brain F-FDG PET data, yielding diagnostic performances that seem promising with respect to those of a commercial post-processing software based on SUVr SD analysis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-020-01490-7DOI Listing

Publication Analysis

Top Keywords

f-fdg pet
16
brain f-fdg
12
interval-valued reconstruction
12
pet analysis
8
alzheimer's disease
8
disease diagnosis
8
post-processing software
8
pet data
8
software based
8
scenium suvr
8

Similar Publications

Purpose: To evaluate the safety, diagnostic accuracy, and factors influencing the diagnostic yield of ultrasound (US)-guided omental biopsies.

Materials And Methods: This retrospective study included 109 patients who underwent US-guided omental biopsies between June 2020 and June 2024. Pre-biopsy diagnostic images (CT, MRI, or [18 F]FDG PET/CT) were reviewed.

View Article and Find Full Text PDF

Prostate cancer (PCa) is a high-prevalence disease usually characterized by metastatic spread to the pelvic lymph nodes and bones and the development of visceral metastases only in the late stages of disease. Positron Emission Tomography (PET) plays a key role in the detection of PCa metastases. Several PET radiotracers are used in PCa patients according to the stage and pathological features of the disease, in particular Ga/F-prostate-specific membrane antigen (PSMA) ligands.

View Article and Find Full Text PDF

Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.

Cancers (Basel)

January 2025

Urology Department, South Metropolitan Health Service, Murdoch, WA, 6150, Australia.

: The role of molecular imaging in urothelial cancer is less defined than other cancers, and its utility remains controversial due to limitations such as high urinary tracer excretion, complicating primary tumour assessment in the bladder and upper urinary tract. This review explores the current landscape of PET imaging in the clinical management of urothelial cancer, with a special emphasis on potential future advancements including emerging novel non-F FDG PET agents, PET radiopharmaceuticals, and PET-MRI applications. : We conducted a comprehensive literature search in the PubMed database, using keywords such as "PET", "PET-CT", "PET-MRI", "FDG PET", "Urothelial Cancer", and "Theranostics".

View Article and Find Full Text PDF

: This study evaluates the diagnostic accuracy of [18F]fluorodeoxyglucose ([F]FDG) positron emission tomography (PET) using bone marrow biopsy (BMB) and clinical follow-up as reference standards. It further identifies predictive factors for bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) patients. : NHL patients who underwent [F]FDG PET and BMB at diagnosis in a tertiary cancer center were included in this study.

View Article and Find Full Text PDF

Hodgkin lymphoma (HL) is a common malignancy among women of reproductive age. Some pregnancies occur during oncological treatments or diagnostic follow-ups, often involving contraindicated procedures. HL is fluorodeoxyglucose-avid; therefore, its staging is generally performed with F-FDG PET/CT, a diagnostic method contraindicated during pregnancy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!